StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $1,006M in Q3 2026, up 21.5% from a year earlier. That is the highest of the 19 quarters on record here.

Latest, Q3 2026
1,006
Period ended Sep 30, 2026
Change on a year earlier
+21.5%
828 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
19
Documents cited below

Where the Q3 2026 figure comes from

“|| Kesimpta | Neuroscience | Relapsing forms of multiple sclerosis (MS) | 1 006 | 21 | 478 | 21 | 23 | 1 484 | 21 | 22”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 20261,006+21.5%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026942+32.1%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026724+23.3%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025815+26.9%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025828+45.0%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025713+28.5%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025587+41.4%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024642+41.7%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024571+40.3%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024555+48.8%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024415+40.7%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023453+48.0%Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023407+70.3%Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023373+82.8%Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023295+71.5%Novartis Form 6-K (0001370368-23-000046) ↗
Q4 2022Dec 31, 2022306–Novartis Form 6-K (0001370368-23-000008) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.